Related Experiment Video

Updated: Jul 1, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

87

Not only a therapeutic target; mTOR in Hodgkin lymphoma and acute lymphoblastic leukemia

Miguel Enrique Cuéllar Mendoza1,2, Francisco Raúl Chávez Sánchez1, Elisa María Dorantes Acosta3

  • 1Department of Biochemistry, Medicine Faculty, National Autonomous University of Mexico, Mexico City, Mexico.

Frontiers in Oncology
|March 6, 2024
PubMed
Abstract

Insights

Mammalian target of rapamycin (mTOR) signaling is elevated in acute lymphoblastic leukemia and Hodgkin lymphoma. This review explores mTOR

Area of Science:

  • Oncology and Hematology research.
  • Molecular signaling pathways in cancer.

Background:

  • The mechanistic/mammalian target of rapamycin (mTOR) is a kinase implicated in various cancers.
  • Dysregulation of mTOR signaling is observed in hematologic neoplasms.
  • This study focuses on mTOR's role in acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma (HL).

Approach:

  • A systematic review was conducted following PRISMA guidelines.
  • Literature search was performed across multiple databases (PubMed, SciELO, etc.) from 1994 to 2023.
  • Included studies focused on mTOR signaling in ALL and HL.

Key Points:

  • mTOR activity is increased in patients with both ALL and HL.
  • Various molecular mechanisms contribute to elevated mTOR activity in these hematologic malignancies.
  • NOTCH, interleukins (4, 7, 9), and nuclear proteins are implicated in mTOR pathway activation.

Conclusions:

  • mTOR signaling plays a significant role in the pathogenesis of acute lymphoblastic leukemia and Hodgkin lymphoma.
  • Understanding mTOR activation mechanisms is crucial for developing targeted therapies.
  • Further research into specific molecular players like NOTCH and interleukins could yield novel therapeutic strategies.
Keywords:
Hodgkin lymphomaacute lymphoblastic leukemiamTORmTORC1mTORC2

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K